Jason Bednar

Q: What is Jason Bednar's success rate?

Jason Bednar currently has a success rate of 96.79109126755789.

Q: What is the average return of Jason Bednar's calls?

Their stock ratings have generated an average return of 16.35450340405666.

Piper Sandler | Healthcare

Jason Bednar is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #1071 out of 4773 analysts, they have issued 32 stock ratings with a success rate of 96.79% and an average return of 16.35%.

Jason Bednar has a well-established track record, with 32 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 96.79% and an average return of 16.35%, underscoring their expertise and ability to identify winning opportunities for investors.

#1071

Out of 4773

Total Ratings

+96.79%

Success Rate

+16.35%

Average Return

Recent Ratings Analysis

COO

Hold

Sep 10, 2026

Target

$86.00

Current

$53.91

Performance

-0.48%

Jason Bednar rated COO as Neutral on Sep 10, 2026, setting a price target of 86. The Hold stance appears justified, as shares hovered around 53.91 with a -0.48% move.

MMSI

Buy

Jul 31, 2026

Target

$106.00

Current

$86.36

Performance

1.59%

On Jul 31, 2026, MMSI was given a Overweight rating by Jason Bednar, with a target price of 106. The stock traded sideways with a 1.59% move, keeping the bullish thesis unresolved.

XRAY

Hold

Jul 29, 2026

Target

$14.00

Current

$10.46

Performance

-26.34%

XRAY received a Neutral rating from Jason Bednar on Jul 29, 2026, aiming for 14. The Hold stance proved prudent, with the market softening by 26.34%.

NVST

Hold

Jul 29, 2026

Target

$26.00

Current

$25.55

Performance

-9.94%

On Jul 29, 2026, Jason Bednar published a Neutral outlook on NVST, with a target of 26. Weakness in the stock, now at 25.55, supported the conservative rating.

HSIC

Buy

Jul 29, 2026

Target

$95.00

Current

$88.36

Performance

2.95%

Jason Bednar on Jul 29, 2026 assigned HSIC a Overweight rating, with a price target of 95. The recommendation remains pending validation as shares consolidate around 88.36.

DRTS

Hold

May 19, 2026

Target

$8.00

Current

$14.43

Performance

35.11%

On May 19, 2026, Jason Bednar reaffirmed DRTS with a Neutral rating, targeting 8. Market strength beyond 14.43 went further than the conservative outlook suggested.

SHC

Buy

May 06, 2026

Target

$22.00

Current

$18.37

Performance

16.27%

SHC was rated Overweight by Jason Bednar on May 06, 2026, with a price objective of 22. A bullish response from the market helped close the gap of 3.63 to the target.

ALGN

Buy

Apr 21, 2026

Target

$235.00

Current

$150.82

Performance

-22.74%

On Apr 21, 2026, Jason Bednar initiated coverage on ALGN with a Overweight rating and target of 235. The Buy call has yet to be validated as shares remain 84.18 away from the target.

GEHC

Buy

Apr 17, 2026

Target

$88.00

Current

$63.93

Performance

-14.37%

Jason Bednar issued a Overweight recommendation for GEHC on Apr 17, 2026, price target set at 88. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

BDX

Hold

Apr 17, 2026

Target

$159.00

Current

$177.85

Performance

12.18%

On Apr 17, 2026, BDX was evaluated by Jason Bednar, who gave a Neutral rating and target of 159. Investors who stayed in despite the Hold saw upside of 12.18%.

ICUI

Buy

Apr 17, 2026

Target

$163.00

Current

$156.48

Performance

20.41%

Jason Bednar rated ICUI as Overweight on Apr 17, 2026, setting a price target of 163. The call has proven timely, with shares rising 20.41% toward the price target of 163.

SOLV

Buy

Apr 17, 2026

Target

$92.00

Current

$87.45

Performance

24.08%

On Apr 17, 2026, SOLV was given a Overweight rating by Jason Bednar, with a target price of 92. The stock rallied 24.08% after the rating, narrowing the gap to the target of 92 and validating the bullish stance.

MDLN

Buy

Jan 12, 2026

Target

$50.00

Current

$32.53

Performance

-23.85%

MDLN received a Overweight rating from Jason Bednar on Jan 12, 2026, aiming for 50. The rating hasn’t played out as hoped, with the stock trading 23.85% below expectations.

MASI

Buy

Aug 06, 2025

Target

$210.00

Current

$179.95

Performance

24.40%

On Aug 06, 2025, Jason Bednar published a Overweight outlook on MASI, with a target of 210. Shares gained 24.40%, underscoring the accuracy of the bullish outlook toward 210.

LUNG

Hold

Jul 31, 2025

Target

$2.50

Current

$1.85

Performance

0.54%

Jason Bednar on Jul 31, 2025 assigned LUNG a Neutral rating, with a price target of 2.5. The Hold stance reflected consolidation, as shares held near 1.85.

NVCR

Buy

Jun 27, 2025

Target

$34.00

Current

$15.51

Performance

-13.83%

On Jun 27, 2025, Jason Bednar reaffirmed NVCR with a Overweight rating, targeting 34. Shares slid 13.83% despite the recommendation, highlighting downside risks.

EDAP

Buy

Mar 28, 2025

Target

$4.50

Current

$4.75

Performance

124.29%

EDAP was rated Overweight by Jason Bednar on Mar 28, 2025, with a price objective of 4.5. A bullish response from the market helped close the gap of -0.25 to the target.

KRMD

Hold

Feb 14, 2025

Target

$4.50

Current

$3.16

Performance

-27.69%

On Feb 14, 2025, Jason Bednar initiated coverage on KRMD with a Neutral rating and target of 4.5. The rating matched the stock’s inability to hold above 3.16.

STE

Buy

Feb 03, 2025

Target

$265.00

Current

$210.76

Performance

-3.47%

Jason Bednar issued a Overweight recommendation for STE on Feb 03, 2025, price target set at 265. The target of 265 remains in play, though confirmation will depend on future moves.

PDCO

Hold

Dec 06, 2024

Target

$24.00

Current

$31.33

Performance

36.69%

On Dec 06, 2024, PDCO was evaluated by Jason Bednar, who gave a Neutral rating and target of 24. Investors who stayed in despite the Hold saw upside of 36.69%.

XAIR

Buy

Jun 25, 2024

Target

$3.50

Current

$3.20

Performance

-98.77%

Jason Bednar rated XAIR as Overweight on Jun 25, 2024, setting a price target of 3.5. The stock has underperformed, dropping 98.77% despite the bullish target of 3.5.

Frequency Asked Questions

Who is Jason Bednar?

Jason Bednar is an analyst from Piper Sandler specializing in the Healthcare sector.

What is Jason Bednar's success rate?

Jason Bednar currently has a success rate of +96.79%.

How many ratings has Jason Bednar issued?

Jason Bednar has issued 32 stock ratings so far.

What is the average return of Jason Bednar's calls?

Their stock ratings have generated an average return of +16.35%.

What is Jason Bednar's ranking?

Jason Bednar is ranked #1071 out of 4773 analysts.

What types of ratings does Jason Bednar give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Jason Bednar?

You can follow Jason Bednar by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Jason Bednar?

Their latest rating was a Hold on COO issued on 2026-09-10.